Drug companies rapped for anticompetitive behaviour


The Italian health ministry is following up on rulings from the country’s competition authorities and demanding billions of euros in damages resulting from anticompetitive behaviour.

The charges relate to Roche and Novartis’s alleged restriction of competition between two related antibody drugs that the two firms co-promote. Lucentis (ranibizumab) and Avastin (bevacizumab) are derived from the same monoclonal antibody that inhibits blood vessel growth.

Avastin is approved for treating certain cancers, whereas Lucentis is used to treat vision loss caused by age-related wet macular degeneration (AMD). But since Avastin is much cheaper, doctors have tended to try and use it off-label to treat AMD. The Italian authorities claim the companies made an agreement to block sales of Avastin in favour of Lucentis, and have asked for €1.2 billion (£977 million) in damages covering 2012–2014. The companies have denied any wrongdoing.

In the same action, the ministry is seeking damages from Pfizer for allegedly abusing its market monopoly position regarding the eye drug Xatalan (latanoprost), by preventing eligible generic versions from entering the market.


Related Content

Roche rapped for side-effect reporting failure

26 June 2012 Business

news image

European medicines regulator names and shames Swiss giant for not disclosing 80,000 instances of potential adverse drug react...

Weathering the storm

6 January 2014 Business

news image

Pharmaceutical industry roundup 2013

Most Read

Better batteries with pure lithium anodes

28 July 2014 Research

news image

Protective carbon nanosphere coating overcomes lithium problems, pointing the way to improved capacity

Takeover battle pushes Allergan to cut R&D jobs

28 July 2014 Business

news image

Besieged by serially acquisitive Valeant, the Botox maker will lay off 1500 staff to propel earnings growth

Most Commented

Bubble wrap could send lab costs packing

23 July 2014 Research

news image

Potential bubbles up across wide range of uses as storage and test vessels, especially for poor countries

Relativity behind mercury's liquidity

21 June 2013 Research

news image

First evidence that relativistic effects are indeed responsible for mercury's low melting point